DUBLIN–(BUSINESS WIRE)–The “Eylea Market Opportunities and Strategies to 2033” report has been added to ResearchAndMarkets.com’s offering. This report describes and explains the Eylea market and covers 2018-2023, termed the historic period, and 2023-…
Author: Business Wire
Pantheon Vision Reflects on a Year of Milestones and Sets Bold Goals for 2025
BALTIMORE–(BUSINESS WIRE)–Pantheon Vision Reflects on a Year of Milestones and Sets Bold Goals for 2025
Dry Eye Disease Epidemiology Forecast Research 2020-2034: Focus on United States, Germany, France, Italy, Spain, United Kingdom, and Japan – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Dry Eye Disease – Epidemiology Forecast – 2034” report has been added to ResearchAndMarkets.com’s offering. The report delivers an in-depth understanding of Dry Eye Disease (DED), historical and forecasted epidemiology of …
National Vision Holdings, Inc. Announces Fourth Quarter and Fiscal 2024 Earnings Release and Conference Call
DULUTH, Ga.–(BUSINESS WIRE)–National Vision Holdings, Inc. (NASDAQ: EYE) (“National Vision” or the “Company”) will report its fourth quarter and fiscal 2024 financial results before the market opens on February 26, 2025 and will host a conference cal…
National Vision Holdings, Inc. Announces Fourth Quarter and Fiscal 2024 Earnings Release and Conference Call
DULUTH, Ga.–(BUSINESS WIRE)–National Vision Holdings, Inc. (NASDAQ: EYE) (“National Vision” or the “Company”) will report its fourth quarter and fiscal 2024 financial results before the market opens on February 26, 2025 and will host a conference cal…
GenSight Biologics Announces Five-Year Efficacy and Safety Results for LUMEVOQ® Gene Therapy at the Conclusion of the REFLECT Study
PARIS–(BUSINESS WIRE)–Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and cent…
GenSight Biologics annonce les résultats d'efficacité et de sécurité à cinq ans de la thérapie génique LUMEVOQ® à l'issue de l'étude REFLECT
PARIS–(BUSINESS WIRE)–Regulatory News: GenSight Biologics (Euronext : SIGHT, ISIN : FR0013183985, éligible au PEA-PME), une société biopharmaceutique spécialisée dans le développement et la commercialisation de thérapies géniques innovantes pour les …
STAAR Surgical Reports Fourth Quarter and Fiscal Year 2024 Results
LAKE FOREST, Calif.–(BUSINESS WIRE)–STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today reported results for the fourth quarter and fiscal…
STAAR Surgical Reports Fourth Quarter and Fiscal Year 2024 Results
LAKE FOREST, Calif.–(BUSINESS WIRE)–STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today reported results for the fourth quarter and fiscal…
TECLens Secures $9.3 Million Series A Funding to Advance Its Non-Invasive Refractive Technology
STAMFORD, Conn.–(BUSINESS WIRE)–TECLens, Inc., a clinical-stage ophthalmic medical device company, announced today it raised $9.3 million in a Series A round co-led by Johnson & Johnson Innovation – JJDC Inc. and Yonjin Capital. Other investors i…
Maui Jim Captures the Essence of Adventure and Connection in the New Vibrant Spring-Summer Advertising Campaign
PEORIA, Ill.–(BUSINESS WIRE)–Maui Jim, premium brand of polarized sunglasses now part of Kering Eyewear portfolio, unveils its new global advertising campaign, Color You Can Feel 2—a renewed invitation to experience the world with even more vivid and…
Aurion Biotech Appoints Donald Munoz as Chief Financial Officer
SEATTLE & CAMBRIDGE, Mass. & TOKYO–(BUSINESS WIRE)–Aurion Biotech, Inc. (Aurion), whose mission is to restore vision to millions of patients with life-changing regenerative therapies, announced today that Donald Munoz is joining the Company as chief …
RadiusXR Announces Strategic Partnership with Thomas Osborne, MD, Chief Medical Officer at Microsoft Federal, and Clinical Professor at Stanford (adjunct)
SAN FRANCISCO–(BUSINESS WIRE)– #Ophthalmology–RadiusXR, a leader in transforming vision testing and eye care with advanced digital health platforms, is thrilled to announce an exciting addition to our team. Thomas Osborne, MD, Chief Medical Officer …
DigitalOptometrics to Preview World’s First Autonomous Slitlamp at Vision Expo East 2025
ORLANDO, Fla.–(BUSINESS WIRE)– #digitaloptometrics–DigitalOptometrics, a leader in remote eye care solutions, is proud to announce the launch of the world’s first and most advanced autonomous slitlamp with remote control capabilities at Vision Expo …
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass.–(BUSINESS WIRE)–Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that a majority of the indep…
MediPrint Ophthalmics Advances Glaucoma Program, Expands Patent Portfolio, and Prepares for Key Industry Presentation
SAN DIEGO–(BUSINESS WIRE)–MediPrint® Ophthalmics, a clinical-stage ophthalmic drug delivery company, continues to advance its innovative glaucoma program following the successful completion of its Phase 2b clinical trial for LL-BMT1. As the company p…
Bausch + Lomb Provides Update on Potential Sale
VAUGHAN, Ontario–(BUSINESS WIRE)–Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, issued the following update on a potential sale, which was disclosed in December 2…
Warby Parker to Announce Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025
NEW YORK–(BUSINESS WIRE)–Warby Parker Inc. (NYSE: WRBY) (the “Company”), a direct-to-consumer lifestyle brand focused on vision for all, today announced that its financial results for the fourth quarter and year ended December 31, 2024 will be releas…
Qlaris Bio Announces Positive Topline Data From Two Phase II Trials of QLS-111 in Patients With Primary Open Angle Glaucoma and Ocular Hypertension
DEDHAM, Mass.–(BUSINESS WIRE)–Qlaris Bio, Inc., a clinical-stage biotechnology company targeting unmet needs in debilitating ophthalmic diseases, today announced positive topline results from two U.S. Phase II clinical trials investigating QLS-111 in…
iVeena Secures $3 Million in Series B-2 Financing to Accelerate Development of IVMED-85 for Myopia
SALT LAKE CITY–(BUSINESS WIRE)–iVeena Delivery Systems Inc. (“iVeena”), a biopharmaceutical company advancing IVMED-85 for the treatment of pediatric myopia, today announced that it has closed its fully subscribed Series B-2 financing of $3 million. …